Evidence map›Paper›PMID 15632077›Full record

ArticleMolecular and cellular biology2005

BRCTx is a novel, highly conserved RAD18-interacting protein.

David J Adams, Louise van der Weyden, Fanni V Gergely, Mark J Arends, Bee Ling Ng, David Tannahill, Roland Kanaar, Andrea Markus, Brian J Morris, Allan Bradley

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

David J AdamsThe Wellcome Trust Sanger Institute Hinxton, Cambs CB10 1SA, United Kingdom.
Louise van der Weyden
Fanni V Gergely
Mark J Arends
Bee Ling Ng
David Tannahill
Roland Kanaar
Andrea Markus
Brian J Morris
Allan Bradley
Wellcome Sanger Institute · GBUniversity of Sydney · AUErasmus University Rotterdam · NLUniversity of Cambridge · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

The BRCT domain is a highly conserved module found in many proteins that participate in DNA damage checkpoint regulation, DNA repair, and cell cycle control. Here we describe the cloning, characterization, and targeted mutagenesis of Brctx, a novel gene with a BRCT motif. Brctx was found to be expressed ubiquitously in adult tissues and during development, with the highest levels found in testis. Brctx-deficient mice develop normally, show no pathological abnormalities, and are fertile. BRCTx binds to the C terminus of hRAD18 in yeast two-hybrid and immunoprecipitation assays and colocalizes with this protein in the nucleus. Despite this, Brctx-deficient murine embryonic fibroblasts (MEFs) do not show overt sensitivity to DNA-damaging agents. MEFs from Brctx-deficient embryos grow at a similar rate to wild-type MEF CD4/CD8 expressions, and the cell cycle parameters of thymocytes from wild-type and Brctx knockout animals are indistinguishable. Intriguingly, the BRCT domain of BRCTx is responsible for mediating its localization to the nucleus and centrosome in interphase cells. We conclude that, although highly conserved, Brctx is not essential for the above-mentioned processes and may be redundant.

Indexed as

Amino Acid SequenceAnimalsBody WeightCarrier ProteinsCell CycleCells, CulturedCentrosomeDNA-Binding ProteinsDNA DamageDNA RepairFibroblastsHumansMaleMiceMice, KnockoutMolecular Sequence DataCarrier ProteinsDNA-Binding ProteinsNuclear ProteinsRAD18 protein, humanUbiquitin-Protein Ligases

Identifiers

PMID15632077
PMCPMC543416
OpenAlexW2125018919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.